PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE Met primary endpoint (NNT~6 for BICLA) & numerical improve
Tweet Content
PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE
Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts
1 MI & 1 death from infection over 213 pts
Encouraging for sure! Second phase 3 being launched
#ACR24 @RheumNow Abstr#L16 #ACRbest https://t.co/QwDMKjhFvb
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off